NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 9, 2024
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income and Comprehensive Income
CONSOLIDATED STATEMENTS INCOME
AND COMPREHENSIVE INCOME
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions, except per share data) | 2023 | 2022 | 2021 |
| Revenues: | |||
| Net product sales | $1,860.6 | $1,440.9 | $1,090.1 |
| Collaboration revenue | 26.5 | 47.8 | 43.4 |
| Total revenues | 1,887.1 | 1,488.7 | 1,133.5 |
| Operating expenses: | |||
| Cost of revenues | 39.7 | 23.2 | 14.3 |
| Research and development | 565.0 | 463.8 | 328.1 |
| Acquired in-process research and development | 143.9 | — | 105.3 |
| Selling, general and administrative | 887.6 | 752.7 | 583.3 |
| Total operating expenses | 1,636.2 | 1,239.7 | 1,031.0 |
| Operating income | 250.9 | 249.0 | 102.5 |
| Other income (expense): | |||
| Interest expense | (4.6) | (7.1) | (25.8) |
| Unrealized gain on equity securities | 28.4 | 30.8 | 20.9 |
| Loss on extinguishment of convertible senior notes | — | (70.0) | — |
| Investment income and other, net | 57.4 | 11.2 | 3.8 |
| Total other income (expense), net | 81.2 | (35.1) | (1.1) |
| Income before provision for income taxes | 332.1 | 213.9 | 101.4 |
| Provision for income taxes | 82.4 | 59.4 | 11.8 |
| Net income | 249.7 | 154.5 | 89.6 |
| Foreign currency translation adjustments, net of tax | 2.4 | 2.9 | — |
| Unrealized gain (loss) on debt securities available-for-sale, net of tax | 12.5 | (9.1) | (3.5) |
| Comprehensive income | $264.6 | $148.3 | $86.1 |
| Earnings per share, basic | $2.56 | $1.61 | $0.95 |
| Earnings per share, diluted | $2.47 | $1.56 | $0.92 |
| Weighted average common shares outstanding, basic | 97.7 | 95.8 | 94.6 |
| Weighted average common shares outstanding, diluted | 101.0 | 98.9 | 97.9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.